Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LY2090314 |
Trade Name | |
Synonyms | LY-2090314|LY 2090314 |
Drug Descriptions |
LY2090314 inhibits glycogen synthase kinase 3 (GSK3), therefore activates Wnt signaling pathway and leads to apoptosis in tumor cells (PMID: 25915038, PMID: 26735141, PMID: 32391602). |
DrugClasses | GSK3 Inhibitor (Pan) 3 |
CAS Registry Number | 603288-22-8 |
NCIT ID | C116849 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + LY2090314 + Pemetrexed Disodium | Carboplatin LY2090314 Pemetrexed Disodium | 0 | 0 |
LY2090314 | LY2090314 | 0 | 0 |
LY2090314 + Niraparib | LY2090314 Niraparib | 0 | 0 |
LY2090314 + Olaparib | LY2090314 Olaparib | 0 | 0 |
LY2090314 + Rucaparib | LY2090314 Rucaparib | 0 | 0 |
LY2090314 + Simmiparib | LY2090314 Simmiparib | 0 | 0 |
LY2090314 + Talazoparib | LY2090314 Talazoparib | 0 | 0 |